Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the
reduction in customer contact leads to a decrease in selling expenses such as expenses related to customers, etc. Furthermore, the cost of impairment loss on financial assets in 2021 decreased by 93.4 million
. Analysis of financial status as at 30 September 2020 (Unit: Million Baht) Assets 30 Sep. 2020 % 30 Sep. 2019 % Trade and other receivables 459.99 22.49% 315.22 19% Inventories 140.18 6.85% 116.98 7% Lease
customer base while also preparing to accommodate new clients this year. Moreover, there was an additional depreciation calculated by the investment in assets used in production to boost efficiency and
additional depreciation calculated by the investment in assets used in production to boost efficiency and reduce production costs in the long run. - Net profit according to the financial statement decreased by
Company’s process of changing its customer base while also preparing to accommodate new clients. Moreover, there was an additional depreciation calculated by the investment in assets used in production to
as at 30 June 2020 (Unit: Million Baht) Assets 30 Jun. 2020 % 31 Dec. 2019 % Trade and other receivables 408.72 20% 315.22 19% Inventories 150.97 7% 116.98 7% Lease receivable 88.03 5% - - Investment
liquidity and to reduce the financial burden. The selling value is 40.48 % when compares to total assets from company consolidated statements. (Market Value 70,370,000.00 x 100 divided by total assets as at
005/2017 24 November 2017 Subject: Informing on the acquisition of assets of ZIGA Innovation Public Company Limited Attention: The President The Stock Exchange of Thailand Attachment: Disclosure of